Drug intelligence / Profile preview

Shixin lozenge

Development stage: Unknown
Lead developer: Hubei Heng'an Fulin Pharmaceutical
Administration: Buccal

Overview

Shixin lozenge (Shixin Hanpian) is a traditional Chinese medicine (TCM) developed by Hubei Hengan Pharmaceutical for the treatment of recurrent aphthous stomatitis (recurrent oral ulcers). It is specifically indicated for patients presenting with the 'stomach fire upward flaring' pattern, a TCM syndrome characterized by painful oral sores, halitosis, and thirst. The therapeutic approach involves clearing heat and purging fire to alleviate pain and accelerate the healing of oral mucosal lesions. A Phase 3 clinical trial (CTR20130821) was conducted in China to evaluate the safety and efficacy of the lozenge in adult patients compared to a placebo.

Brand names: Shixin lozenge
Other names: Shixin Hanpian视欣含片

Beyond the preview

Go deeper on Shixin lozenge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shixin lozenge.

Explore the full profile